Gelonghui, April 22丨Cansino Biotech (06185.HK) announced that the freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine developed by the company has been approved by the China National Drug Administration and can carry out relevant clinical trials.
Haemophilus influenzae is a gram-negative bacillus and is one of the most common pathogens of acute lower respiratory infections in children. It is divided into capsular type and non-perpendicular type, both of which can cause infection. Non-capsular strains often cause diseases such as otitis media and sinusitis. It is mainly caused by nasopharyngeal colonizing bacteria spreading to nearby sites; infections secondary to bloodstream attacks are usually caused by capsular strains. Capsular strains are classified according to the chemical composition of capsular polysaccharides. Six serotypes have been discovered so far. Of these, about 95% of invasive Haemophilus influenzae diseases are caused by type b.
The Hib vaccine developed by the company is a covalent combination of purified Hib capsular polysaccharide and tetanus toxoid protein. It is expected to induce humoral immunity against Hib after vaccination and provide protection to vaccinators.